The 2020 Gastrointestinal Cancers Symposium: What to Expect
Cancer Therapy Advisor’s coverage of the Gastrointestinal Cancers Symposium will reflect the theme of personalized care across multiple types of gastrointestinal cancers.
All articles by Cancer Therapy Advisor Staff
Phase 1b/2 Trial Assessing Cirmtuzumab With Ibrutinib in Patients With B-Cell Lymphoid Malignancies
Part 1 of the trial is a dose-finding evaluation of the sequential administration of cirmtuzumab monotherapy followed by cirmtuzumab and ibrutinib combination.
Phase 2 Trial to Assess Ibrutinib in Patients With Relapsed Hairy Cell Leukemia
The researchers hypothesize that ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Phase 2 Trial of Ixazomib and Rituximab in Bruton Tyrosine Kinase Inhibitor-Resistant Mantle Cell Lymphoma
Reseachers hypothesize that ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Clinical Trial to Evaluate Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Researchers are conducting a multicenter, open-label, phase 1/2 study of oral LOXO-305 in patients with CLL/SLL and non-Hodgkin lymphoma.
The 2019 San Antonio Breast Cancer Symposium: What to Expect
Talks from the meeting will offer insights on the prevention and diagnosis of disease, and will also compare novel therapeutic interventions with older standards of care.
ESMO Congress 2019: What to Expect
Preview key science that will be presented during the European Society of Medical Oncology’s 2019 Congress.
Phase 3 Trial Compares Standard-Dose Versus High-Dose Combination Chemo With Stem Cell Transplant for Germ Cell Tumors
Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
LIBRETTO-121: A Phase 1/2 Trial Investigating LOXO-292 in Pediatric Patients With Advanced Solid or Primary CNS Tumors
A primary outcome measure for phase 1 of the trial is determining the safety of oral LOXO-292.
Phase 1/2 Study of Durvalumab and Tremelimumab in Pediatric Cancer
After phase 1, the study will expand in a second phase to test the efficacy of these drugs at the determine dosage.
Next post in Pediatric Cancer
